NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that David Wambeke has joined the company as Chief Business Officer and concurrently purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share, the closing price on February 27, 2026. The appointment and insider purchase underscore the company's commitment to advancing its drug delivery program and expanding its commercial footprint.
Wambeke will lead NeuroOne's drug delivery program, refine product requirements for preclinical and clinical-stage devices, expand relationships with key opinion leaders, and engage prospective pharmaceutical partners. He will also oversee investor relations and support strategic business development, including partnerships and corporate transactions. CEO Dave Rosa highlighted Wambeke's rare combination of public company experience and capital markets expertise, stating, "As we continue to execute on our strategy and expand awareness of NeuroOne's technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities."
Wambeke previously served as Chief Business Officer at DiaMedica Therapeutics, where he led the expansion of a lead biologic into preeclampsia and oversaw a successful Phase 2 clinical trial. Prior to that, he spent 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army and was awarded the Purple Heart after being wounded in combat in Baghdad, Iraq.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. "With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology. As the company scales commercialization, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation."
The net proceeds from the share sale will support ongoing clinical and product development activities, as well as working capital and general corporate purposes. The shares were sold in a private placement exempt from registration under the Securities Act.
In connection with his appointment, NeuroOne granted Wambeke an inducement stock option to purchase 500,000 shares at $0.6704 per share, with a 10-year term and four-year vesting schedule. The grant was approved by the compensation committee and was a material inducement for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs.
